No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabri­va Ther­a­peu­tics suf­fered a set­back af­ter the FDA re­ject­ed its an­tibi­ot­ic for com­pli­cat­ed uri­nary tract in­fec­tions — the No­var­tis spin­off has now had some bet­ter luck with the US agency, which on Mon­day ap­proved its oth­er drug for com­mu­ni­ty-ac­quired bac­te­r­i­al pneu­mo­nia.

The drug, lefa­mulin, has been de­vel­oped as an in­tra­venous and oral for­mu­la­tion and been test­ed in two late-stage clin­i­cal tri­als. The se­mi-syn­thet­ic com­pound, whose dos­ing can be switched be­tween the two for­mu­la­tions, is en­gi­neered to in­hib­it the syn­the­sis of bac­te­r­i­al pro­tein by bind­ing to a part of the bac­te­r­i­al ri­bo­some.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER